Literature DB >> 3160527

Nitrendipine kinetics in normal and impaired renal function.

G R Aronoff, R S Sloan.   

Abstract

To test the hypothesis that renal failure alters the absorption and metabolism of nitrendipine and the renal elimination of its metabolites, we gave six normal men and 16 men with various degrees of renal dysfunction a single 20 mg oral dose of nitrendipine. Plasma nitrendipine and nitrendipine pyridine analog metabolite concentrations were measured by HPLC 14 times during 48 hours after dosing. The urinary excretion of four additional metabolites was measured. Standing and supine arterial blood pressure was measured 14 times during the 48 hours after dosing. The mean nitrendipine t1/2 was 2.8 +/- 2.1 hours and that of the metabolite was 3.4 +/- 3.9 hours. No significant effect of decreased renal function on any kinetic parameter was demonstrated. Plasma nitrendipine concentrations correlated with decreased blood pressure, but metabolite concentrations did not. We conclude that renal insufficiency does not alter nitrendipine kinetics in man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160527     DOI: 10.1038/clpt.1985.161

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure.

Authors:  T Ankermann; U Osterkamp; S R Santos; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing.

Authors:  J van Harten; J Burggraaf; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

5.  Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Authors:  G Mikus; V Mast; C Fischer; C Machleidt; U Kuhlmann; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

6.  Inter- and intra-subject variability of nitrendipine and the effects of food.

Authors:  J Lobo; D B Jack; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.

Authors:  V Mast; C Fischer; G Mikus; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 8.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

9.  Pharmacokinetics of nitrendipine in terminal renal failure.

Authors:  L van Bortel; R Böhm; J Mooy; P Schiffers; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 10.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.